Metastasiertes kleinzelliges Bronchialkarzinom ohne nachweisbaren Primärtumor

 

 Permissions and Reprints

Zusammenfassung

Wir berichten über einen 61 Jahre alten Patienten, der aufgrund einer progredienten Dysphagie, Heiserkeit und inspiratorischem Stridor vorstellig wurde. Das TCT dokumentierte ausgeprägte Metastasen in der Schilddrüse und der linken Nebenniere. Histologisch wurde ein kleinzelliges Bronchialkarzinom nachgewiesen. Ein pulmonaler Primarius war nicht nachweisbar. Durch die platinumbasierte Chemotherapie konnte eine gute Symptomkontrolle erzielt werden.

Abstract

We report on a 61-year-old male patient who was admitted due to dysphagia, hoarseness and stridor. CT showed extensive metastasis to the thyroid and left adrenal gland. Histology revealed small-cell lung cancer. A primary tumour could not be detected in the lungs and mediastinum. Good symptom control could be achieved by administration of platinum-based chemotherapy,

Literatur

• 1 Jemal A, Siegel R, Ward E et al. Cancer statistics 2008.  CA Cancer J Clin. 2008;  58 71-96
  CrossrefPubMedGoogle Scholar
• 2 Govindan R, Page N, Morgenstern D et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database.  J Clin Oncol. 2006;  24 4539-44
  CrossrefPubMedGoogle Scholar
• 3 Groome P A, Bolejach V, Crowley J J et al. The IASLC Lung Cancer Staging Project: Validation of the proposals for Revision of the T,N, and M Descriptors and Consequent Stage Grouping in the Forthcoming Edition of the TNM Classification of malignant tumors.  J Thorac Oncol. 2007;  2 694-705
  CrossrefPubMedGoogle Scholar
• 4 Hermes A, Waschki B, Gatzemeier U et al. Characteristics, treatment patterns and outcomes of patients with small cell lung Cancer – A retrospective single institution analysis.  Lung Cancer. 2011;  71 363-366
  CrossrefPubMedGoogle Scholar
• 5 Haider K, Shahid R, Finch D et al. Extrapulmonary small cell cancer.  Cancer. 2006;  107 2262-2269
  CrossrefPubMedGoogle Scholar
• 6 Brennan S, Gregory D, Stillie A et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer?.  Cancer. 2010;  116 888-895
  CrossrefPubMedGoogle Scholar
• 7 Hanna N, Bunn Jr. P A, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.  J Clin Oncol. 2006;  24 2038-2043
  CrossrefPubMedGoogle Scholar
• 8 Hermes A, Bergman B, Bremnes R et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.  J Clin Oncol. 2008;  26 4261-4267
  CrossrefPubMedGoogle Scholar
• 9 Heigener D F, Freitag L, Eschbach C et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial.  J Clin Oncol.. 2008;  26 (suppl) Abstr 7513
  PubMedGoogle Scholar
• 10 Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer.  New Engl J Med.. 2007;  357 664-672
  CrossrefPubMedGoogle Scholar

Dr. Andreas Hermes

Onkologischer Schwerpunkt
Krankenhaus Großhansdorf

Wöhrendamm 80
22927 Großhansdorf

Email: pahermes@hotmail.com